AR105102A1 - Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen - Google Patents
Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienenInfo
- Publication number
- AR105102A1 AR105102A1 ARP160101880A ARP160101880A AR105102A1 AR 105102 A1 AR105102 A1 AR 105102A1 AR P160101880 A ARP160101880 A AR P160101880A AR P160101880 A ARP160101880 A AR P160101880A AR 105102 A1 AR105102 A1 AR 105102A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- branched
- linear
- ring
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 18
- 125000000217 alkyl group Chemical group 0.000 abstract 18
- 229910052757 nitrogen Inorganic materials 0.000 abstract 15
- 125000003118 aryl group Chemical group 0.000 abstract 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 239000001301 oxygen Substances 0.000 abstract 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 6
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 239000011593 sulfur Substances 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000006684 polyhaloalkyl group Polymers 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000006574 non-aromatic ring group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Medicamentos. Reivindicación 1: Compuesto de fórmula (1), en la que: A representa el grupo de fórmula (2), en la que 1 está unido al grupo W y 2 está unido al anillo fenilo, en la que: E representa un anillo furilo, tienilo o pirrolilo; X¹, X³, X⁴ y X⁵ independientemente uno de otro representan un átomo de carbono o un átomo de nitrógeno; X² representa un grupo C-R²¹ o un átomo de nitrógeno; y el anillo de línea punteada (del grupo de fórmula (2)) significa que el anillo es aromático; R¹ representa un átomo de halógeno, un grupo alquilo C₁₋₆ lineal o ramificado, un grupo alquenilo C₂₋₆ lineal o ramificado, un grupo alquinilo C₂₋₆ lineal o ramificado, un grupo polihaloalquilo C₁₋₆ lineal o ramificado, un grupo hidroxi, un grupo hidroxialquilo C₁₋₆, un grupo alcoxi C₁₋₆ lineal o ramificado, -S-alquilo C₁₋₆, un grupo ciano, un grupo nitro, -alquilo C₀₋₆-NR¹¹R¹¹, -O-alquilo C₁₋₆-NR¹¹R¹¹, -O-alquilo C₁₋₆-R¹², -C(O)-OR¹¹, -O-C(O)-R¹¹, -C(O)-NR¹¹R¹¹, -NR¹¹-C(O)-R¹¹, -NR¹¹-C(O)-OR¹¹, -alquilo C₁₋₆-NR¹¹-C(O)-R¹¹, -SO₂-NR¹¹R¹¹, -SO₂-alquilo C₁₋₆; R², R³, R⁴ y R⁵ independientemente uno de otro representan un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ lineal o ramificado, un grupo alquenilo C₂₋₆ lineal o ramificado, un grupo alquinilo C₂₋₆ lineal o ramificado, un polihaloalquilo C₁₋₆ lineal o ramificado, un grupo hidroxi, un grupo hidroxialquilo C₁₋₆, un grupo alcoxi C₁₋₆ lineal o ramificado, un grupo -S-alquilo C₁₋₆, un grupo ciano, un grupo nitro, -alquilo C₀₋₆-NR¹¹R¹¹, -O-alquilo C₁₋₆-NR¹¹R¹¹, -O-alquilo C₁₋₆-R¹², -C(O)-OR¹¹, -O-C(O)-R¹¹, -C(O)-NR¹¹R¹¹, -NR¹¹-C(O)-R¹¹, -NR¹¹-C(O)-OR¹¹, -alquilo C₁₋₆-NR¹¹-C(O)-R¹¹, SO₂-NR¹¹R¹¹, o -SO₂-alquilo C₁₋₆, o los sustituyentes de la pareja (R¹, R²) forman conjuntamente con los átomos de carbono a los que están unidos un anillo aromático o no aromático compuesto por de 5 a 7 miembros en el anillo, que puede contener de 1 a 3 heteroátomos seleccionados de oxigeno, azufre y nitrógeno, entendiéndose que el anillo resultante puede estar sustituido con de 1 a 2 grupos seleccionados de halógeno, alquilo C₁₋₆ lineal o ramificado, -alquilo C₀₋₆-NR¹¹R¹¹, -NR¹³R¹³, -alquilo C₀₋₆-Cy¹ u oxo; R⁶ y R⁷ independientemente uno de otro representan un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ lineal o ramificado, un grupo alquenilo C₂₋₆ lineal o ramificado, un grupo alquinilo C₂₋₆ lineal o ramificado, un polihaloalquilo C₁₋₆ lineal o ramificado, un grupo hidroxi, un grupo alcoxi C₁₋₆ lineal o ramificado, un grupo -S-alquilo C₁₋₆, un grupo ciano, un grupo nitro, -alquilo C₀₋₆-NR¹¹R¹¹, -O-Cy¹, -alquilo C₀₋₆-Cy¹, -alquenilo C₂₋₆-Cy¹, -alquinilo C₂₋₆-Cy¹, -O-alquilo C₁₋₆-R¹², -C(O)-OR¹¹, -O-C(O)-R¹¹, -C(O)-NR¹¹R¹¹, -NR¹¹-C(O)-R¹¹, -NR¹¹-C(O)-OR¹¹, -alquilo C₁₋₆-NR¹¹-C(O)-R¹¹, -SO₂-NR¹¹R¹¹, -SO₂-alquilo C₁₋₆, o los sustituyentes de la pareja (R⁶, R⁷), cuando se injertan en dos átomos de carbono adyacentes, forman conjuntamente con los átomos de carbono a los que están unidos un anillo aromático o no aromático compuesto por de 5 a 7 miembros en el anillo, que puede contener de 1 a 3 heteroátomos seleccionados de oxígeno, azufre y nitrógeno, entendiéndose que el anillo resultante puede estar sustituido con un grupo seleccionado de un grupo alquilo C₁₋₆ lineal o ramificado, -NR¹³R¹³ -alquilo C₀₋₆-Cy¹, o un oxo; W representa un grupo -CH₂-, un grupo -NH- o un átomo de oxígeno; R⁸ representa un átomo de hidrógeno, un grupo alquilo C₁₋₈ lineal o ramificado, un grupo -CHRᵃRᵇ, un grupo arilo, un grupo heteroarilo, un grupo arilalquilo C₁₋₆, o un grupo heteroarilalquilo C₁₋₆; R⁹ representa un átomo de hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado, un grupo alquenilo C₂₋₆ lineal o ramificado, un grupo alquinilo C₂₋₆ lineal o ramificado, -Cy², -alquilo C₁₋₆-Cy², -alquenilo C₂₋₆-Cy², -alquinilo C₂₋₆-Cy², -Cy²-Cy³, -alquinilo C₂₋₆-O-Cy², -Cy²-alquilo C₀₋₆-O-alquilo C₀₋₆-Cy³, un átomo de halógeno, un grupo ciano, -C(O)-R¹⁵, o -C(O)-NR¹⁵R¹⁵; R¹⁰ representa un átomo de hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado, un grupo alquenilo C₂₋₆ lineal o ramificado, un grupo alquinilo C₂₋₆ lineal o ramificado, un grupo arilalquilo C₁₋₆, un grupo cicloalquilalquilo C₁₋₆, un polihaloalquilo C₁₋₆ lineal o ramificado, -alquilo C₁₋₆-O-Cy⁴, o los sustituyentes de la pareja (R⁹, R¹⁰), cuando se injertan en dos átomos de carbono adyacentes, forman conjuntamente con los átomos de carbono a los que están unidos un anillo aromático o no aromático compuesto por de 5 a 7 miembros en el anillo, que puede contener de 1 a 3 heteroátomos seleccionados de oxígeno, azufre y nitrógeno; R¹¹ y R¹¹ independientemente uno de otro representan un átomo de hidrógeno, un grupo alquilo C₁₋₆ lineal o ramificado, o los sustituyentes de la pareja (R¹¹, R¹¹) forman conjuntamente con el átomo de nitrógeno al que están unidos un anillo aromático o no aromático compuesto por de 5 a 7 miembros en el anillo, que puede contener además del átomo de nitrógeno de 1 a 3 heteroátomos seleccionados de oxígeno, azufre y nitrógeno, entendiéndose que el nitrógeno en cuestión puede estar sustituido con un grupo que representa un átomo de hidrógeno, o un grupo alquilo C₁₋₆ lineal o ramificado; R¹² representa -Cy⁵, -Cy⁵-alquilo C₀₋₆-O-alquilo C₀₋₆-Cy⁶, -Cy⁵-alquilo C₀₋₆-Cy⁶, -Cy⁵-alquilo C₀₋₆-NR¹¹-alquilo C₀₋₆-Cy⁶, -Cy⁵-Cy⁶-O-alquilo C₀₋₆-Cy⁷, -C(O)-NR¹¹R¹¹, -NR¹¹R¹¹, -OR¹¹, -NR¹¹-C(O)-R¹¹, -O-alquilo C₁₋₆-OR¹¹, -SO₂-R¹¹, -C(O)-OR¹¹, o -NH-C(O)-NH-R¹¹; R¹³, R¹³, R¹⁵ y R¹⁵ independientemente uno de otro representan un átomo de hidrógeno, o un grupo alquilo C₁₋₆ lineal o ramificado sustituido opcionalmente; R¹⁴ representa un átomo de hidrógeno, un grupo hidroxi, o un grupo hidroxialquilo C₁₋₆; R²¹ representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ lineal o ramificado, o un grupo ciano; Rᵃ representa un átomo de hidrógeno o un grupo alquilo C₁₋₆ lineal o ramificado; Rᵇ representa un grupo -O-C(O)-O-Rᶜ, un grupo -O-C(O)-NRᶜRᶜ, o un grupo -O-P(O)(ORᶜ)₂; Rᶜ y Rᶜ independientemente uno de otro representan un átomo de hidrógeno, un grupo alquilo C₁₋₈ lineal o ramificado, un grupo cicloalquilo, un grupo alcoxi C₁₋₆alquilo C₁₋₆, un grupo alcoxi C₁₋₆carbonilalquilo C₁₋₆, o los sustituyentes de la pareja (Rᶜ, Rᶜ) forman conjuntamente con el átomo de nitrógeno al que están unidos un anillo no aromático compuesto por de 5 a 7 miembros en el anillo, que puede contener además del átomo de nitrógeno de 1 a 3 heteroátomos seleccionados de oxígeno y nitrógeno, entendiéndose que el nitrógeno en cuestión puede estar sustituido con un grupo que representa un grupo alquilo C₁₋₆ lineal o ramificado; Cy¹, Cy², Cy³, Cy⁴, Cy⁵, Cy⁶ y Cy⁷ independientemente uno de otro, representan un grupo cicloalquilo, un grupo heterocicloalquilo, un grupo arilo, o un grupo heteroarilo; n es un número entero igual a 0 ó 1; entendiéndose que: arilo significa un grupo fenilo, naftilo, bifenilo, indanilo o indenilo; heteroarilo significa cualquier grupo mono- o bi-cíclico compuesto por de 5 a 10 miembros en el anillo, que tiene al menos un resto aromático y que contiene de 1 a 3 heteroátomos seleccionados de oxígeno, azufre y nitrógeno; cicloalquilo significa cualquier grupo carbocíclico no aromático mono- o bi-cíclico que contiene de 3 a 10 miembros en el anillo; heterocicloalquilo significa cualquier grupo carbocíclico no aromático mono- o bi-cíclico que contiene de 3 a 10 miembros en el anillo, y que contiene de 1 a 3 heteroátomos seleccionados de oxígeno, azufre y nitrógeno, que puede incluir sistemas de anillos fusionados, con puente o espiro, siendo posible para los grupos arilo, heteroarilo, cicloalquilo y heterocicloalquilo así definidos y los grupos alquilo, alquenilo, alquinilo, alcoxi, estar sustituidos con de 1 a 4 grupos seleccionados de alquilo C₁₋₆ lineal o ramificado sustituido opcionalmente, alquenilo C₂₋₆ lineal o ramificado sustituido opcionalmente, alquinilo C₂₋₆ lineal o ramificado sustituido opcionalmente, alcoxi C₁₋₆ lineal o ramificado sustituido opcionalmente, alquilo C₁₋₆-S- sustituido opcionalmente, hidroxi, oxo (o N-óxido cuando sea apropiado), nitro, ciano, -C(O)-OR, -O-C(O)-R, -C(O)-NRR, -O-C(O)-NRR, -NRR, -(C=NR)-OR, -O-P(O)(OR)₂, -O-P(O)(O⁻M⁺)₂, polihaloalquilo C₁₋₆ lineal o ramificado, trifluorometoxi, halógeno, o una aldohexosa de fórmula (3) ó (4) en la que cada R es independiente; entendiéndose que R y R independientemente uno de otro representan un átomo de hidrógeno o un grupo alquilo C₁₋₆ lineal o ramificado sustituido opcionalmente; y M⁺ representa un catión monovalente farmacéuticamente aceptable; con la condición de que el compuesto de fórmula (5) no puede representar un compuesto de fórmula (6); sus enantiómeros, diastereoisómeros y atropisómeros, y sales de adición de estos con un ácido o base farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1555750A FR3037959B1 (fr) | 2015-06-23 | 2015-06-23 | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105102A1 true AR105102A1 (es) | 2017-09-06 |
Family
ID=54356456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101880A AR105102A1 (es) | 2015-06-23 | 2016-06-23 | Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen |
Country Status (42)
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
WO2018015526A1 (en) | 2016-07-22 | 2018-01-25 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof |
UA125142C2 (uk) * | 2017-01-06 | 2022-01-19 | Ле Лаборатуар Сервьє | Комбінація інгібітору mcl-1 і таксанової сполуки, її застосування та фармацевтична композиція |
UY37560A (es) | 2017-01-06 | 2018-07-31 | Servier Lab | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta |
SG11201911891WA (en) | 2017-06-22 | 2020-01-30 | Servier Lab | Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof |
BR112020003163A2 (pt) * | 2017-08-15 | 2020-09-15 | AbbVie Deutschland GmbH & Co. KG | inibidores macrocíclicos de mcl-1 e métodos de uso |
BR112020003180A2 (pt) | 2017-08-15 | 2020-09-15 | AbbVie Deutschland GmbH & Co. KG | inibidores macrocíclicos de mcl-1 e métodos de uso |
CN111372936B (zh) * | 2017-11-23 | 2022-12-02 | 北京赛林泰医药技术有限公司 | Mcl-1选择性抑制剂及其制备和用途 |
TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
AR116635A1 (es) | 2018-10-15 | 2021-05-26 | Servier Lab | Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen |
TW202038960A (zh) | 2018-11-14 | 2020-11-01 | 法商施維雅藥廠 | Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物 |
KR101973074B1 (ko) * | 2018-11-30 | 2019-04-26 | 주식회사 티움바이오 | 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물 |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
PE20220218A1 (es) | 2019-05-20 | 2022-02-02 | Novartis Ag | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso |
AR119156A1 (es) | 2019-06-17 | 2021-11-24 | Servier Lab | Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma |
JP2022551083A (ja) * | 2019-10-03 | 2022-12-07 | カリフォルニア インスティチュート オブ テクノロジー | Mcl1インヒビター及びその使用 |
US20230125057A1 (en) * | 2020-01-09 | 2023-04-20 | University Of Washington | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy |
EP4251208A1 (en) | 2020-11-24 | 2023-10-04 | Novartis AG | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
WO2022216946A1 (en) * | 2021-04-07 | 2022-10-13 | California Institute Of Technology | Mcl1 inhibitors and uses thereof |
US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
JP2024520801A (ja) | 2021-06-11 | 2024-05-24 | ギリアード サイエンシーズ, インコーポレイテッド | Mcl-1阻害剤と抗がん剤との組み合わせ |
TW202408588A (zh) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | 抗體-藥物結合物抗腫瘤化合物及其使用方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP9900330A3 (en) | 1995-07-06 | 2001-08-28 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
EP1922321A1 (en) * | 2005-08-09 | 2008-05-21 | Eirx Therapeutics Ltd | Pyrazoloý1,5-a¨pyrimidine compounds and pharmaceutical compositions containing them |
AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
CN102264745B (zh) * | 2008-11-10 | 2015-07-22 | 财团法人卫生研究院 | 作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物 |
AU2009328584B2 (en) | 2008-12-18 | 2016-05-12 | Bayer Cropscience Aktiengesellschaft | Tetrazole substituted anthranilic acid amides as pesticides |
CN102030742B (zh) | 2009-09-28 | 2013-06-19 | 齐鲁制药有限公司 | 作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物 |
CN102464667B (zh) * | 2010-11-03 | 2014-06-04 | 中国科学院上海药物研究所 | 一类五元杂环并嘧啶类化合物及其制备方法和用途 |
US8722676B2 (en) * | 2011-11-03 | 2014-05-13 | Genentech, Inc. | Bicyclic piperazine compounds |
AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2015
- 2015-06-23 FR FR1555750A patent/FR3037959B1/fr not_active Expired - Fee Related
-
2016
- 2016-06-16 UY UY0001036734A patent/UY36734A/es unknown
- 2016-06-22 CR CR20170575A patent/CR20170575A/es unknown
- 2016-06-22 TN TNP/2017/000524A patent/TN2017000524A1/en unknown
- 2016-06-22 RS RS20201419A patent/RS61179B1/sr unknown
- 2016-06-22 HU HUE16730854A patent/HUE051877T2/hu unknown
- 2016-06-22 EP EP16730854.3A patent/EP3313817B1/en active Active
- 2016-06-22 JO JOP/2016/0127A patent/JO3674B1/ar active
- 2016-06-22 DK DK16730854.3T patent/DK3313817T3/da active
- 2016-06-22 SI SI201631022T patent/SI3313817T1/sl unknown
- 2016-06-22 TW TW105119604A patent/TW201712006A/zh unknown
- 2016-06-22 UA UAA201800621A patent/UA122498C2/uk unknown
- 2016-06-22 PT PT167308543T patent/PT3313817T/pt unknown
- 2016-06-22 MX MX2017016995A patent/MX2017016995A/es unknown
- 2016-06-22 ES ES16730854T patent/ES2831749T3/es active Active
- 2016-06-22 EA EA201890126A patent/EA033566B1/ru unknown
- 2016-06-22 WO PCT/EP2016/064418 patent/WO2016207217A1/en active Application Filing
- 2016-06-22 MD MDE20180438T patent/MD3313817T2/ro unknown
- 2016-06-22 US US15/738,186 patent/US10323041B2/en active Active
- 2016-06-22 CA CA2990084A patent/CA2990084C/en active Active
- 2016-06-22 RU RU2018102368A patent/RU2760554C1/ru active
- 2016-06-22 AU AU2016282828A patent/AU2016282828B2/en active Active
- 2016-06-22 PL PL16730854T patent/PL3313817T3/pl unknown
- 2016-06-22 JP JP2017566289A patent/JP6741699B2/ja active Active
- 2016-06-22 CU CU2017000163A patent/CU24466B1/es unknown
- 2016-06-22 KR KR1020187002027A patent/KR20180015264A/ko not_active Application Discontinuation
- 2016-06-22 PE PE2017002717A patent/PE20181491A1/es active Application Revival
- 2016-06-22 GE GEAP201614681A patent/GEP20207056B/en unknown
- 2016-06-22 CN CN201680048560.1A patent/CN108137497B/zh active Active
- 2016-06-22 MA MA42230A patent/MA42230B1/fr unknown
- 2016-06-22 LT LTEP16730854.3T patent/LT3313817T/lt unknown
- 2016-06-23 AR ARP160101880A patent/AR105102A1/es unknown
-
2017
- 2017-12-13 SV SV2017005589A patent/SV2017005589A/es unknown
- 2017-12-13 CO CONC2017/0012832A patent/CO2017012832A2/es unknown
- 2017-12-14 PH PH12017502315A patent/PH12017502315A1/en unknown
- 2017-12-14 CL CL2017003205A patent/CL2017003205A1/es unknown
- 2017-12-15 EC ECIEPI201783003A patent/ECSP17083003A/es unknown
- 2017-12-15 ZA ZA2017/08562A patent/ZA201708562B/en unknown
- 2017-12-18 IL IL256375A patent/IL256375B/en active IP Right Grant
-
2018
- 2018-10-24 HK HK18113624.7A patent/HK1254656A1/zh unknown
-
2019
- 2019-04-25 US US16/394,308 patent/US10618909B2/en active Active
-
2020
- 2020-11-05 HR HRP20201782TT patent/HRP20201782T1/hr unknown
- 2020-12-10 CY CY20201101170T patent/CY1123645T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR105102A1 (es) | Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR105103A1 (es) | Derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR105101A1 (es) | Derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR105104A1 (es) | Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR098906A1 (es) | Derivados de tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR108706A1 (es) | Derivados piperidinilo, un proceso para su preparación, y composiciones farmacéuticas que los contienen | |
AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR101179A1 (es) | Combinaciones anti-pd-l1 para tratar tumores | |
AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
AR103252A1 (es) | Compuestos de quinazolina | |
AR094550A1 (es) | Inhibidores de btk | |
PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR092742A1 (es) | Piridinonas antifibroticas | |
AR117616A1 (es) | Compuestos anti-vih | |
AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
AR093339A1 (es) | Analogos de spliceostatina y metodos para su preparacion | |
AR097009A1 (es) | Compuestos isoindolina o isoquinolina, un proceso para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para diferentes tipos de cáncer | |
AR099914A1 (es) | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR098492A1 (es) | Derivados de purina | |
AR090293A1 (es) | Inhibidores de quinasa a base de arileter | |
AR105875A1 (es) | Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio | |
AR111983A1 (es) | ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a | |
AR102799A1 (es) | Profármacos de agonistas fenólicos de trpv1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |